… targeting PD-1/PD-L1 have demonstrated significant efficacy. These antibody drugs function
by blocking … mentioned a class of small molecular inhibitors targeting PD-1/PD-L1 with a …

… , blockade of PD-1 or CTLA-4 with ICPIs may break self-tolerance and trigger an autoimmune
response against a specific self-antigen on an organ like the kidney. … the efficacy of steroids …

… cells through downregulation of the mTOR pathway [49]. … To date, antibodies to therapeutically
target the PD-1:PD-… small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin’…

… and efficacy of a short course of anti-PD-1 immunotherapy … drug targeting TIM-1, has shown
a controlled toxicity profile … cellular browning by regulating uncoupling protein 1 (UCP1) level …

… signals are the direct targets for ICB, as PD-1 and CTLA4 are both … for potential toxic side
effects of targeting metabolism in other … metabolism can become uncoupled, and inhibition of …

… PD-1 blockade rejuvenates primarily effector functions, … overview of the risk and
efficacy of ICI management in SOTR. … 49%) of kidney-transplant patients treated with anti-PD-1/PD-L1 …

… the major dose-limiting toxicity associated with T cell engaging … use of mTOR and JAK
inhibitors support the uncoupling of CD19… This further supports the mTOR pathways as a target to …

… that it is possible to uncouple immunosuppression and immune … One patient had both a kidney
and a heart transplant. Most … Mechanistic studies on the effect of mTORi on PD-1 blockade …

… The mechanisms of renal toxicity may be various ranging … by programmed death protein 1
(PD-1) and its ligand (PD-L1). In … to uncouple allograft tolerance from their anti-tumoral action. …

… targeting programmed cell death protein 1 (PD-1) and its … shown high efficacy against tumors
with low toxicity to normal … for combination therapy with PD-1 inhibitors in the treatment of …